Printed from the IBC Life Sciences Web site on February 6, 2016 6:36 AM ET.
Page location: http://www.ibclifesciences.com/19392.xml
IBC's 13th Annual Well Characterized Biologicals conference is loaded with the latest new content to help you overcome your protein characterization challenges and develop strategies to implement new technologies in your own laboratories.
With 6 presentations from the FDA, 6 from Genentech, 4 from Amgen, 3 from Biogen Idec, 3 from Pfizer, 2 from Merck, 2 from MedImmune and others by BMS, Lilly and Genzyme, it's no secret why IBC's Well Characterized Biologicals conference has been such a well respected, must-attend event in the bioprocess industry for over 12 years.
New This Year! Well Characterized Biologicals will be immediately followed by IBC's intensive, science and strategy-focused two day conference on De-Risking Next Generation Biologics: Capabilities & Strategies to Develop BioBetters, Biosimilars and Follow-ons. Stay the full week and you will not only maximize your travel dollar, but you will also have the chance to learn how innovator, generic and technology companies companies are reducing risk and capitalizing on new opportunities in biologics drug development across the spectrum of products from BioBetters to Biosimilars and Follow-ons.